Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.
Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.
All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) and Mammoth Biosciences, Inc. collaborate to advance in vivo CRISPR-based gene editing therapies for multiple diseases. Regeneron's AAV vectors and Mammoth's ultracompact gene editing systems aim to target tissues beyond the liver. Mammoth receives $100 million upfront payment and equity investment, with potential milestone payments totaling up to $370 million per target. Regeneron gains access to Mammoth's editing technologies for a period of five and a half years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will showcase new data and updates on its oncology and hematology pipeline at the ASCO 2024 Annual Meeting. The presentations will cover investigational treatments for a variety of solid tumors and blood cancers, including REGN7075, a promising costimulatory bispecific antibody in combination with Libtayo. The company's commitment to cancer research and development of innovative therapies is evident in the diverse pipeline of checkpoint inhibitors and bispecific antibodies being presented at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. to showcase genetic medicine research advancements at ASGCT conference, including results from clinical study of otoferlin gene therapy DB-OTO for genetic hearing loss. The company will present data on delivery systems, immune response modulation, and sustained treatment expression. Regeneron aims to overcome obstacles in genetic medicine implementation through innovative approaches. Promising early results from gene therapy programs raise hope for future treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. presents positive pivotal data on linvoseltamab for relapsed/refractory multiple myeloma at AACR Annual Meeting 2024. The data show promising results with high response rates, durable responses, and good safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) will report its Q1 2024 financial results on May 2, 2024. A conference call and webcast will be held at 8:30 AM Eastern Time. Participants can join via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Summary
SillaJen submits CSR to the US FDA for REN026, a study on Pexa-Vec and cemiplimab in RCC patients. The study shows positive safety and efficacy results, with high response rates and overall survival. Collaboration with Regeneron Pharmaceuticals yields promising outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. receives Complete Response Letters from the FDA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma due to enrollment status issues in confirmatory trials. Despite this, no concerns were raised regarding clinical efficacy, safety, design, labeling, or manufacturing. Regeneron is actively enrolling patients in Phase 3 trials as part of the OLYMPIA program, aiming to revolutionize B-cell non-Hodgkin lymphoma treatment. The company is dedicated to collaborating with the FDA to expedite the availability of odronextamab for patients. Updates on enrollment and regulatory timelines are expected later this year, while EMA review continues for R/R DLBCL and R/R FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
-
Rhea-AI Summary
Achyuta Rajaram, 17, from Exeter, NH, wins the top award of $250,000 in the Regeneron Science Talent Search 2024. The competition, in its 83rd year, highlights young innovators in STEM fields. Other winners include Thomas Cong and Michelle Wei.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA approval to extend the use of Praluent for children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). The approval allows Praluent to be used as an adjunct to diet and other LDL-C lowering therapies, providing a new treatment option for children with high LDL-C levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. announces positive results for EYLEA HD in treating wet age-related macular degeneration and diabetic macular edema. The Lancet published one-year data from PULSAR and PHOTON trials showing non-inferior vision gains with extended dosing regimens compared to standard care. EYLEA HD offers durable visual improvements, fluid control, and reduced treatment burden for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
Regeneron Pharmaceuticals
Nasdaq:REGN
REGN Rankings
REGN Stock Data
61.57B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
United States
TARRYTOWN